The prevalence and associated factors of metabolic syndrome among patients with end-stage renal failure undergoing hemodialysis in Indonesia. Issue 6 (November 2020)

• Record Type: Journal Article
• Authors: Syukri, Maimun; Virnardo, Ricky; Salwani, Desi; Abdullah, ; Sofyan, Hizir; Marthoenis,
• Is Part Of: Diabetes & metabolic syndrome. Volume 14:Issue 6(2020)
• Page Start: 2069
• Page End: 2072
• Publication Date: 2020-11
• Subjects: Metabolic syndrome -- Hemodialysis -- Prevalence -- Chronic renal failure; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2020.10.019
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aims: Various components of Metabolic Syndrome (MetS) have been studied in general population, but few among patients undergoing hemodialysis (HD). This study aims to assess the metabolic profiles and to estimate the prevalence of MetS among patients with End-Stage Renal Failure (ESRF) undergoing HD. Methods: Patients undergoing HD during October 2016–August 2017 in three General Hospitals in Aceh - Indonesia were included in the study. MetS was defined according to the modified NCEP-ATP III criteria for South Asians. Results: The overall prevalence of MetS was 50.2%. Male patients have higher MetS prevalence (58.3%) than female (41.7%). MetS was only associated with gender and history of diabetes, and not with other demographic variables. Alteration central obesity was the most common metabolic abnormality among the patients (57.2%), followed by hypertension (30.7%), diabetes (30%), raised triglycerides (27.4%) and reduced HDL (23.7%). Pre-metabolic syndrome was found in 48.3%, leaving only 1.4% of patients free from metabolic abnormality. Conclusions: Half of the patients undergoing HD in Indonesia suffered from MetS and almost half had pre-metabolic syndrome. High rate of metabolic abnormalities in patients with ESRF requires intensive examination and collaboration between nephrologists and endocrinologists to prevent the deterioration of patients' condition during HD. Highlights: We estimated the prevalence of MetS among ESRF patients undergoing hemodialysis in Indonesia. Approximately half of the patients (50.2%) suffered from MetS and another half (48.3%) had pre-metabolic syndrome. MetS was only associated with gender and history of diabetes.